Liraglutide Ameliorates Hyperhomocysteinemia-Induced Alzheimer-Like Pathology and Memory Deficits in Rats via Multi-molecular Targeting

No abstract is available for this paper.

• Publication year

  2019

• Venue

  Neuroscience Bulletin

• Publication date

  2019-01-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s12264-018-00336-7PMID 30632006PMCID PMC6616622
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums

  2018cited by this paper
• Cystatin C Induces Insulin Resistance in Hippocampal Neurons and Promotes Cognitive Dysfunction in Rodents

  2018cited by this paper
• Prevalence and clinical-demographic correlates of hyperhomocysteinemia in inpatients with bipolar disorder in a Han Chinese population.

  2018cited by this paper
• Subcutaneous liraglutide ameliorates methylglyoxal-induced Alzheimer-like tau pathology and cognitive impairment by modulating tau hyperphosphorylation and glycogen synthase kinase-3β.

  2017cited by this paper
• Golgi-Cox Staining Step by Step

  2016cited by this paper
• Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease.

  2014cited by this paper
• Liraglutide Exerts Antidiabetic Effect via PTP1B and PI3K/Akt2 Signaling Pathway in Skeletal Muscle of KKAy Mice

  2014cited by this paper
• The nature, significance, and glucagon‐like peptide‐1 analog treatment of brain insulin resistance in Alzheimer's disease

  2014cited by this paper
• Betaine attenuates Alzheimer‐like pathological changes and memory deficits induced by homocysteine

  2013cited by this paper
• Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline.

  2012cited by this paper
• An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers.

  2012cited by this paper
• Reducing Amyloid-Related Alzheimer's Disease Pathogenesis by a Small Molecule Targeting Filamin A

  2012cited by this paper
• (Val⁸) glucagon-like peptide-1 prevents tau hyperphosphorylation, impairment of spatial learning and ultra-structural cellular damage induced by streptozotocin in rat brains.

  2012cited by this paper
• Regulation of insulin sensitivity by serine/threonine phosphorylation of insulin receptor substrate proteins IRS1 and IRS2

  2012cited by this paper
• Decreased Glucagon-Like Peptide-1 Receptor Immunoreactivity in the Dentate Granule Cell Layer from Adult in the Gerbil Hippocampus

  2011cited by this paper
• Folate/vitamin-B12 Prevents Chronic Hyperhomocysteinemia-Induced Tau Hyperphosphorylation and Memory Deficits in Aged Rats

  2011cited by this paper
• Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease.

  2009cited by this paper
• Hyperhomocysteinemia increases beta-amyloid by enhancing expression of gamma-secretase and phosphorylation of amyloid precursor protein in rat brain.

  2009cited by this paper
• GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid.

  2008cited by this paper
• Homocysteine induces tau phosphorylation by inactivating protein phosphatase 2A in rat hippocampus.

  2008cited by this paper
• IRS1-independent defects define major nodes of insulin resistance.

  2008cited by this paper
• Protein Phosphatase 2A Methyltransferase Links Homocysteine Metabolism with Tau and Amyloid Precursor Protein Regulation

  2007cited by this paper
• Hyperhomocysteinemia induces insulin resistance in male Sprague-Dawley rats.

  2007cited by this paper
• Central glucagon like peptide-1 delays solid gastric emptying via central CRF and peripheral sympathetic pathway in rats.

  2006cited by this paper
• Morris water maze: procedures for assessing spatial and related forms of learning and memory

  2006cited by this paper
• Abeta42 is essential for parenchymal and vascular amyloid deposition in mice.

  2005cited by this paper
• The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose.

  2003cited by this paper
• Insulin resistance in patients with polycystic ovary syndrome is associated with elevated plasma homocysteine.

  2003cited by this paper
• APP processing is regulated by cytoplasmic phosphorylation

  2003cited by this paper
• Glucagon-like peptide-1 receptor is involved in learning and neuroprotection

  2003cited by this paper
• Distribution of glucokinase, glucose transporter GLUT2, sulfonylurea receptor-1, glucagon-like peptide-1 receptor and neuropeptide Y messenger RNAs in rat brain by quantitative real time RT-PCR.

  2003cited by this paper
• The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion.

  2002cited by this paper
• Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes.

  2002cited by this paper
• Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase ADAM 10

  2001cited by this paper
• BACE1 is the major β-secretase for generation of Aβ peptides by neurons

  2001cited by this paper
• BACE1 is the major beta-secretase for generation of Abeta peptides by neurons.

  2001cited by this paper
• Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha -secretase ADAM 10.

  2001cited by this paper
• Dose-related effects of GLP-1 on insulin secretion, insulin sensitivity, and glucose effectiveness in mice.

  1999cited by this paper
• Dose-related effects of GLP-1 on insulin secretion, insulin sensitivity, and glucose effectiveness in mice.

  1999cited by this paper
• Insulin resistance is associated with elevated plasma total homocysteine levels in healthy, non-obese subjects.

  1998cited by this paper
• Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation.

  1997cited by this paper
• Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem.

  1997cited by this paper
• Clinical Features of Early-Onset Alzheimer Disease in a Large Kindred With an E280A Presenilin-1 Mutation

  1997cited by this paper
• Desensitization of the neuronal insulin receptor: a new approach in the etiopathogenesis of late-onset sporadic dementia of the Alzheimer type (SDAT)?

  1995cited by this paper
• Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43).

  1994cited by this paper
• Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: Evidence that an initially deposited species is Aβ42(43)

  1994cited by this paper
• Desensitization of brain insulin receptor. Effect on glucose/energy and related metabolism.

  1994cited by this paper
• Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology.

  1986cited by this paper
• Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein

  1984cited by this paper

• Liraglutide attenuates aluminum chloride-induced Alzheimer’s disease in rats by modulating the oxLDL/LPA/LPAR1 pathway

  2026cites this paper
• Therapeutic efficacy of synthetic analogues of gut hormones in a mouse model of Alzheimer's disease.

  2026cites this paper
• Associations Between Diabetes Mellitus and Neurodegenerative Diseases

  2025cites this paper
• Progress in Anti-ageing Drug Research for Age-related Diseases: A Review.

  2025cites this paper
• Effect of antidiabetic drugs in Alzheimer´s disease: a systematic review of preclinical and clinical studies

  2025cites this paper
• Antidiabetic GLP-1 Receptor Agonists Have Neuroprotective Properties in Experimental Animal Models of Alzheimer’s Disease

  2025influential citation
• Homocysteine‐potentiated Kelch‐like ECH‐associated protein 1 promotes senescence of neuroblastoma 2a cells via inhibiting ubiquitination of β‐catenin

  2024cites this paper
• The Mechanism and Treatment of Cognitive Dysfunction in Diabetes: A Review

  2024cites this paper
• Liraglutide alleviated Alpha-pyrrolidinovalerophenone (α-PVP) induced Cognitive deficits in rats by modifying brain mitochondrial impairment.

  2024cites this paper
• Neuroprotective effect of liraglutide and memantine in a rat model of Alzheimer’s disease

  2024cites this paper
• GLP-1/GIP Agonist as an Intriguing and Ultimate Remedy for Combating Alzheimer's Disease through its Supporting DPP4 Inhibitors: A Review.

  2024cites this paper
• Pharmacological Approaches Using Diabetic Drugs Repurposed for Alzheimer’s Disease

  2024cites this paper
• Clinical antidiabetic medication used in Alzheimer’s disease: From basic discovery to therapeutics development

  2023cites this paper
• Crosstalk between Alzheimer’s disease and diabetes: a focus on anti-diabetic drugs

  2023cites this paper
• Challenges and Opportunities of Metal Chelation Therapy in Trace Metals Overload-Induced Alzheimer’s Disease

  2023cites this paper
• The Role of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) in Diabetes-Related Neurodegenerative Diseases

  2022cites this paper
• Homocysteine-Potentiated Keap1 Promotes Neuronal Senescence via Inhibiting Ubiquitination of β-Catenin

  2022cites this paper
• MiR‐483‐3p improves learning and memory abilities via XPO1 in Alzheimer's disease

  2022cites this paper
• The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease

  2022cites this paper
• Alternative role of glucagon-like Peptide-1 receptor agonists in neurodegenerative diseases.

  2022cites this paper
• Molecular and Biochemical Pathways Encompassing Diabetes Mellitus and Dementia.

  2021cites this paper
• Hyperhomocysteinemia: Metabolic Role and Animal Studies with a Focus on Cognitive Performance and Decline—A Review

  2021cites this paper
• Alzheimer's Disease and Type 2 Diabetes Mellitus: similarities in pathomechanisms lead to therapeutic opportunities.

  2021cites this paper
• Role of liraglutide in Alzheimer’s disease pathology

  2021influential citation
• Liraglutide Improves Cognitive and Neuronal Function in 3-NP Rat Model of Huntington’s Disease

  2021cites this paper
• Calcium Dyshomeostasis in Alzheimer’s Disease Pathogenesis

  2021cites this paper
• Liraglutide, 7,8-DHF and their co-treatment prevents loss of vision and cognitive decline in a Wolfram syndrome rat model

  2021cites this paper
• Anti-stress effects of the glucagon-like peptide-1 receptor agonist liraglutide in zebrafish

  2021cites this paper
• Liraglutide Protects Against Brain Amyloid-β1–42 Accumulation in Female Mice with Early Alzheimer’s Disease-Like Pathology by Partially Rescuing Oxidative/Nitrosative Stress and Inflammation

  2020cites this paper
• Protein Phosphatase 2A as a Drug Target in the Treatment of Cancer and Alzheimer’s Disease

  2020cites this paper
• Direct Activation of Protein Phosphatase 2A (PP2A) by Tricyclic Sulfonamides Ameliorates Alzheimer’s Disease Pathogenesis in Cell and Animal Models

  2020cites this paper
• Bottom up proteomics identifies neuronal differentiation pathway networks activated by cathepsin inhibition treatment in neuroblastoma cells that are enhanced by concurrent 13-cis retinoic acid treatment.

  2020cites this paper
• Adiponectin: The Potential Regulator and Therapeutic Target of Obesity and Alzheimer’s Disease

  2020cites this paper
• Type 2 Diabetes Mellitus Drugs for Alzheimer's Disease: Current Evidence and Therapeutic Opportunities.

  2020cites this paper
• Current understanding of metal ions in the pathogenesis of Alzheimer’s disease

  2020cites this paper
• Insulin signaling as a therapeutic target in Alzheimer’s disease: Efficacy of apomorphine

  2020cites this paper
• Hippocampal-Dependent Inhibitory Learning and Memory Processes in the Control of Eating and Drug Taking.

  2020cites this paper